Lactulose: Clinical Trials

24 trials of Lactulose, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 9 unknown, 2 terminated, 1 recruiting. 24 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 424Completed 11, Unknown 9, Terminated 2, Recruiting 1, Withdrawn 1

Follow Lactulose: new trials by email Literature Review of Lactulose trials Research Report on Lactulose

Trials (filtered) newest first · largest first

All 24 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE
Oral Branched chain Amino acid, Rifaximin 550 MG, Lactulose - Hepatic Encephalopathy, Decompensated Cirrhosis
Phase 4RecruitingPost Graduate Institute of Medical Education and Research, Chandigarh3362025-02-012026-11-17
A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy.
Probiotic plus lactulose, Rifaximin plus lactulose, L-ornithine-L-aspartate plus latulose - Overt Hepatic Encephalopathy
Phase 4CompletedQurratul Ain Jamil2522024-12-022025-06-25
Clinical Study on the Application of Lactulose Combined with Linaclotide in Bowel Preparation for Colonoscopy
Lactulose, Lactulose+ linaclotide, polyethylene glycol (PEG) - Lactulose, Bowel Preparation
Phase 4UnknownHaifeng Lan4442024-09-012024-12-27
Bowel Preparation in Colonoscopy: Lactulose vs Polyethyleneglycol, Randomized Double-blind Comparative Clinical Trial, Multicenter Study.
Bowel preparation before colonoscopy - Colorectal Cancer Screening
Phase 4CompletedHospital Civil de Guadalajara4492024-07-202026-07-28
Efficacy of L-Ornithine L-Aspartate and Polyethylene Glycol in Cirrhotic Patients With Overt Hepatic Encephalopathy
Polyethylene Glycols, Lactulose oral solution, L-ornithine L-aspartate - Hepatic Encephalopathy Stage 2, Hepatic Encephalopathy Stage 3
Phase 4UnknownJinnah Postgraduate Medical Centre3602023-10-012023-07-13
Effectiveness of Oral Lactulose Versus Lactulose Enema in Hepatic Encephalopathy
Tap water, Lactulose - Hepatic Encephalopathy, Chronic Liver Disease
Phase 4UnknownKhyber Medical College, Peshawar1002023-04-012023-04-05
Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders
Linaclotide, Lactulose, Omeprazol - Functional Dyspepsia, Constipation-predominant Irritable Bowel Syndrome
Phase 4UnknownRenJi Hospital782021-01-012021-12-13
Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Cirrhosis;(PEGHE Trial)
Polyethylene Glycols, Lactulose - Hepatic Encephalopathy
Phase 4UnknownAga Khan University1022020-03-092023-04-19
Mode of Action of Ondansetron, a 5-HT Receptor 3 Antagonist, in Lactulose Induced Diarrhoea
Ondansetron 8mg, abdominal MRI, Lactulose - Motility Disorder of Intestine, Ondansetron
Phase 4CompletedUniversity of Nottingham162018-10-162019-11-27
PEG3350 in ACLF With Hepatic Encephalopathy
PEG-3350 with Electolytes, Lactulose - Hepatic Encephalopathy, Acute-On-Chronic Liver Failure
Phase 4UnknownPost Graduate Institute of Medical Education and Research, Chandigarh602018-05-202019-06-17
Peritoneal Dialysis Pilot Study: Evaluating Polyethylene Glycol (PEG) for Constipation
Current Bowel Protocol (senna/lactulose), PEG Bowel Protocol (PEG/lactulose) - Constipation, Peritoneal Dialysis Complication
Phase 4CompletedNova Scotia Health Authority252017-07-072024-08-21
PEG (Polyethylene Glycol)Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy
Lactulose, Polyethylene Glycol - Hepatic Encephalopathy
Phase 4UnknownSherief Abd-Elsalam1002017-03-112017-04-27
Efficacy and Safety of Prucalopride in Combination With Polyethylene Glycol or Lactulose in Women With Chronic Constipation
Prucalopride, Polyethylene glycol (PEG), Lactulose - Constipation
Phase 4CompletedXian-Janssen Pharmaceutical Ltd.2802014-10-142017-09-15
Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding
Lactulose, L-ornithine L-aspartate, Rifaximin - Hepatic Encephalopathy
Phase 4CompletedHospital General de Mexico882014-07-012018-05-22
Quality of Life and Nutritional Improvements in Cirrhotic Patients
Rifaximin, Lactulose, Lactulose Placebo - Liver Cirrhosis, Hepatic Encephalopathy
Phase 4TerminatedTampa General Hospital42013-04-012013-09-23
The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy
Rifaximin, Lactulose - Hepatic Encephalopathy, Cirrhosis
Phase 4CompletedBausch Health Americas, Inc.2222013-01-082019-09-09
A Preference Study Comparing Kristalose® and Liquid Lactulose
lactulose (Kristalose®), liquid lactulose - Constipation
Phase 4CompletedCumberland Pharmaceuticals502009-06-012011-09-27
Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy
L-ornithine-L-aspartate and lactulose, placebo and lactulose - Hepatic Encephalopathy
Phase 4CompletedMahidol University352008-09-012020-09-04
Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis
Lactulose, Probiotics(VSL#3) - Hepatic Encephalopathy
Phase 4UnknownGovind Ballabh Pant Hospital2008-09-012010-08-10
Rifaximin Versus Lactulose in Renal Failure
Rifaximin, Lactulose - Liver Cirrhosis, Renal Failure
Phase 4WithdrawnWeill Medical College of Cornell University2008-06-012022-02-08

Showing 20 of 24. Sign in to see all of them.

Conditions studied

Hepatic Encephalopathy (13)  ·  Constipation (4)  ·  Liver Cirrhosis (4)  ·  Fibrosis (3)  ·  Hepatic Insufficiency (2)  ·  Liver Diseases (2)  ·  Acute-On-Chronic Liver Failure (1)  ·  Bone Diseases, Metabolic (1)  ·  Brain Diseases (1)  ·  Colorectal Neoplasms (1)  ·  Fissure in Ano (1)  ·  Hemorrhoids (1)  ·  Hypertension, Portal (1)  ·  Irritable Bowel Syndrome (1)  ·  Liver Failure (1)

Sponsors

Post Graduate Institute of Medical Education and Research, Chandigarh (3)  ·  Govind Ballabh Pant Hospital (2)  ·  Solvay Pharmaceuticals (2)  ·  Aga Khan University (1)  ·  Bausch Health Americas, Inc. (1)  ·  Cumberland Pharmaceuticals (1)  ·  Haifeng Lan (1)  ·  Hospital Civil de Guadalajara (1)  ·  Hospital General de Mexico (1)  ·  Jinnah Postgraduate Medical Centre (1)  ·  Khyber Medical College, Peshawar (1)  ·  Mahidol University (1)  ·  Nova Scotia Health Authority (1)  ·  Qurratul Ain Jamil (1)  ·  RenJi Hospital (1)

Countries

India (5)  ·  United States (4)  ·  China (3)  ·  Pakistan (3)  ·  Mexico (2)  ·  Spain (2)  ·  Canada (1)  ·  Egypt (1)  ·  Thailand (1)  ·  United Kingdom (1)

Top investigators

Barjesh C Sharma, MD,DM (2)  ·  Aliena Badshah (1)  ·  Amany Abd El-Rahim Abdin, MD (1)  ·  Guy Neff, MD, MBA (1)  ·  Hala Hany Shehata, Msc (1)  ·  Hanan Soliman, MD (1)  ·  Jaclyn Y Tran, BScPharm (1)  ·  Ji Xuan (1)  ·  Lindsey Mathew (1)  ·  Madhumita Premkumar, DM (1)  ·  Om Parkash (1)  ·  QurratulAin Jamil, PhD (1)  ·  Radha K Dhiman, MD,DM, FACG (1)  ·  Robin Spiller (1)

Results publications

PMID 17326150, PMID 30079329, PMID 33060437, PMID 37467180, PMID 40079184, PMID 41272855